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Introduction
External-beam radiation therapy (RT) in combination with androgen deprivation therapy (ADT) using gonadotropinreleasing hormone (GnRH) agonist therapy decreases cancer-specific mortality and, in some cases, all-cause mortality for men with intermediate/high-risk or locally advanced prostate cancer (PCa) [1] [2] [3] [4] [5] [6] . In part, given this demonstrated survival benefit in intermediate/high-risk disease, GnRH agonist therapy use has increased markedly during the past 2 decades in men with PCa including men with lower stage disease and in older men with significant competing causes of mortality [7] [8] [9] . However, caution has been raised regarding ADT use with heightened consideration in those least likely to benefit (ie, lower risk disease with less competing causes of mortality) and those most likely to be harmed (ie, significant comorbidities such as high-risk cardiovascular status) because the risk-benefit ratio is less well defined in these patient populations.
Most but not all population-based analyses have suggested that GnRH agonists are associated with a greater risk of incident coronary artery disease, myocardial infarction, and diabetes (DM) in men with PCa [10] [11] [12] . Subsequent reports suggested that men with comorbidities or prior cardiovascular disease (CVD) treated with GnRH agonists may have an increased risk of cardiovascular mortality (CVM) [13, 14] . Following these observations, a science advisory consensus statement on GnRH agonist therapy and cardiovascular risk was issued, and a US Food and Drug Administration safety warning addressing the concern of increased risk of myocardial infarction, stroke, sudden cardiac death, and DM was released [15] . However, conflicting results exist regarding the risks of ADT and CVM because a number of analyses from phase III randomized trials and subsequent meta-analysis showed no increased risk of CVM in patients treated with GnRH agonists [16] [17] [18] [19] . These studies largely consisted of patients with highrisk and locally advanced disease. As such, significant controversy remains surrounding the potential effects of GnRH agonist therapy on cardiovascular death, especially in men with lower cancer-specific mortality and in men with baseline cardiac risk factors.
Thus to assess the relationship between GnRH agonist therapy and CVM in patients with clinically localized PCa, we conducted an exploratory and unplanned retrospective analysis of data from a large randomized trial, Radiation Therapy Oncology Group (RTOG) 94-08, of men treated by RT with or without short-term ADT [1] .
Patients and methods
The data used in this hypothesis-generating analysis were derived from RTOG 94-08, a phase III trial designed to compare RT with or without 4 mo of GnRH agonist therapy in men with stage T1b-2b PCa and with prostate-specific antigen (PSA) <20 ng/ml [1] . Following stratification based on PSA level (<4 vs 4-20 ng/ml), tumor grade (well differentiated, moderately differentiated, poorly differentiated), and surgical versus clinical documentation of clinically negative nodal status, patients were randomized to RT plus short-term ADT or RT alone [1] .
Patient eligibility
Patients had histologically confirmed prostate adenocarcinoma, stage
T1b-2b and a PSA level 20 ng/ml. Pretreatment assessment included digital rectal examination and bone scan. Regional lymph nodes were assessed by surgical sampling, lymphangiography, or pelvic computed tomography. Karnofsky performance score was !70. All participating sites were required to have institutional review board approval, and all patients provided written informed consent.
Treatment
Details of RT technique, doses, and fields, and follow-up were previously described [1] . Patients assigned to short-term ADT received flutamide 250 mg three times a day and either monthly 3.6 mg goserelin subcutaneously or 7.5 mg leuprolide intramuscularly for 4 mo.
End points
Cause of death was investigator defined and reported on follow-up case report forms by each institution. All corresponding end-point times were measured from date of randomization until death or last follow-up.
Death due to any cause was an event for overall survival (OS). Death due to PCa was an event for disease-specific survival (DSS 
Statistics
The purpose of this analysis was to generate a hypothesis regarding the relationship between ADT and CVM. For OS, the Cox proportional hazards model was used. For DSS and CVM, the Fine-Gray proportional hazards model was used [20] . Age and PSA were treated as continuous variables in all analyses. All p values are two sided; p values <0.05 were considered significant. Analyses assessing interaction of prostate cancer risk group and treatment arm were restricted to patients with data for all covariates tested (n = 1933).
Results

Pretreatment characteristics
Between 1994 and 2001, a total of 1979 eligible patients were enrolled in the trial. Overall, 987 patients were assigned to RT and short-course ADT; 992 patients were assigned to RT alone. Median age was 71 yr. Median follow-up was 9.1 yr for patients alive at the last data collection (range: 0.1-14.1 yr). Pretreatment characteristics including GS, PSA, and T stage were balanced between treatment arms ( Figure 1 depicts OS, DSS, and CVM based on treatment arm. There was no increase in CVM in patients treated with ADT. At 10 yr, 83 men (cumulative incidence rate: 10%) on the RT and ADT arm and 95 men (cumulative incidence rate: 11%) on the RT-alone arm experienced CVM. This is a difference of 1.0% (95% CI, À2.0 to 3.9). The relatively narrow CI and its inclusion of 0 suggest there is no meaningful difference in the 10-yr rate of CVM. The corresponding unadjusted HR was 1.07 and did not meet statistical significance (95% CI, 0.81-1.42; p = 0.62) ( Table 2) .
CVM was significantly associated with traditional cardiac risk factors including age (HR: 1.05; p = 0.0003), baseline CVD (HR: 2.14; p < 0.0001), and baseline DM (HR: 1.93; p < 0.0001). Baseline HTN did not reach conventional levels of statistical significance (HR: 1.33; p = 0.054) ( Table 2 ). There was no interactive effect between any ADT = androgen-deprivation therapy; CVD = cardiovascular disease; DM = diabetes mellitus; HTN = hypertension; PSA = prostate-specific antigen; RT = radiation therapy; SD = standard deviation.
individual cardiac risk factor and treatment arm with respect to CVM.
Risk group analyses
Analyses were performed to evaluate the relationship between baseline risk factor groupings and mortality.
Patients with a higher risk for CVM (age !70 yr and presence of baseline CVD or DM) composed 22% of the study population ( 
Discussion
Using data from a large randomized controlled trial with a long follow-up, we demonstrated that short-course ADT improves OS and DSS and does not appear to increase CVM in patients with clinically localized PCa. Our results are uniquely positioned to address the controversy surrounding ADT use because this study analyzed patients from all risk groups and provides a novel perspective for patients with lower cancer-specific mortality risk. Approximately 90% of the patients analyzed had low-or intermediate-risk disease. Our findings regarding the lack of association between ADT and CVM are consistent with the observed actuarial 10-yr rates of death due to intercurrent disease previously reported between the treatment arms of RTOG 94-08 (35% RT and ADT vs 37% RT alone; p = 0.49) and with prior analyses from large randomized trials that failed to identify increased CVM in patients with locally advanced and highrisk disease [16] [17] [18] 21, 22] . These studies included patients with a significantly higher cancer-specific mortality risk that could mask a small effect in CVM, in contrast to the predominantly low-and intermediate-risk population of this study.
Although our results are encouraging regarding lack of observed CVM in patients treated with short-course ADT, the absence of any observed survival benefit to the addition of hormone therapy in men receiving radiation for low-risk disease does not support routine use of ADT in this patient population. Given that nearly all deaths in this group result from non-PCa causes, the addition of any toxicity from ADT is not warranted.
Based on results from RTOG 94-08, the predicted number of intermediate-risk patients needed to treat with shortcourse ADT in addition to RT for each death prevented at 8 yr is approximately 17. Consistent with these results, our subgroup analysis demonstrated a significant DSS benefit for the addition of short-course ADT to RT in intermediaterisk patients.
In high-risk and locally advanced disease, the number of patients needed to treat with long-term ADT to prevent one death based on large randomized studies is estimated at three to five. This large treatment effect has set the standard of care for higher risk disease. Although there was no OS or DSS benefit observed in our analyses for patients with highrisk disease based on treatment arm, this was likely due to an inadequate duration of ADT (4 mo instead of the longer term standard of 28-36 mo) and the comparatively small number of high-risk patients included in the trial.
To address the concern that a subset of patients with baseline comorbidities may have increased risk for treatment-related mortality, our analyses demonstrated that ADT was not associated with CVM even when adjusting for age and preexisting cardiac risk factors including CVD and DM. These results were maintained despite a slight increase in baseline CVD in patients randomized to the ADT and RT arm. However we cannot exclude the possibility of a small treatment effect on CVM or that an unidentified subset of patients (including those with prior CV comorbidity using a validated metric) are at risk for ADT-related harm. Results from RTOG 08-15 will provide clarification on the role for ADT with modern escalated RT doses in patients with intermediate-risk disease and known baseline comorbidities.
Although population-based studies have associated ADT with coronary heart disease, myocardial infarction, stroke, ADT = androgen-deprivation therapy; CI = confidence interval; CVD = cardiovascular disease; DM = diabetes mellitus; HR = hazard ratio; HTN = hypertension; PSA = prostate-specific antigen; RL = referent level; RT = radiation therapy. * Cumulative incidence estimates; death due to other cause is considered as a competing risk. y Fine-Gray method; death due to other cause is considered as a competing risk. ADT = androgen-deprivation therapy; CI = confidence interval; CVM = cardiovascular mortality; DSS = disease-specific survival; HR = hazard ratio, OS = overall survival; RL = referent level. * Cumulative incidence estimates; death due to other cause is considered as a competing risk. y Fine-Gray method; death due to other cause is considered as a competing risk.
and metabolic changes including weight gain, sarcopenia, dyslipidemia, insulin resistance, and DM, the magnitude of effect on CVD has been modest (eg, number needed to harm estimated at 384 for each additional myocardial infarction) [10, 11, [23] [24] [25] [26] [27] . These studies often lack robust risk group stratification and are limited in design to prove cause-andeffect relationships including a causal role for ADT and CVM [28] . It may be that GnRH agonist therapy leads to metabolic changes with mixed effects on predicted cardiovascular risk. For example, ADT may lead to increased low-density lipoprotein cholesterol and decreased insulin sensitivity (increasing risk) but increased high-density lipoprotein cholesterol (decreasing risk) and no effect on blood pressure or C-reactive protein levels [23, 27] . As such, any direct metabolic effects may result in a net neutral or insignificant effect on CVM.
Our study has substantial strengths including that it is derived from a large randomized multicenter trial with a control arm of no hormone therapy and long follow-up, and it contains many events to inform our primary analysis. Importantly, the trial includes all PCa risk groups including those with and without DSS or OS advantage to ADT, as well as patients at high risk for cardiac mortality due to existing comorbidities. However, this study did not collect sufficient data to perform analyses regarding comorbidity risk using validated metrics or cancer risk assessment using other multivariable instruments. Although the potential exists for ascertainment bias surrounding cause of death and definition of our primary end point, the recording of cardiac death does appear reliable given the strong association with traditional cardiac risk factors including age, baseline CVD, and DM.
It is reassuring that the observed trial deaths attributed to CVM (approximately 24%) are consistent with cardiac mortality rates (approximately 25%) in the general population during the time period of the study [29] . We further considered that ADT may increase the risk of cerebrovascular disease. However, we observed a limited number of deaths attributed to cerebrovascular disease in this study (10 events in the RT and ADT arms; 14 events in the RT arm) precluding any significant statistical conclusions. Additional information relating to lifestyle factors such as smoking, diet, physical activity, and use of concomitant cardiac medications was not collected in RTOG 94-08.
Conclusions
We demonstrated that short-course GnRH agonist therapy is not associated with CVM in patients with clinically localized PCa enrolled on RTOG 94-08. These findings are inclusive of all PCa risk groups and provide important insight into lowand intermediate-risk patients with less competing causes of mortality. The lack of cardiac mortality associated with ADT use extends to patients at low risk for cancer-specific mortality and to patients at high risk for cardiac mortality due to age and the presence of baseline cardiovascular risk factors including CVD and DM. In addition, we demonstrate that OS and DSS are associated with short-course GnRH agonist therapy and RT, principally in intermediate-risk patients. While treatment decisions must always weigh potential risks and benefits, our data support the continued use of ADT in settings with proven survival benefit.
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